Zybrestat fosbretabulin: Phase Ib/II started

OxiGene began an open-label, U.K. Phase Ib/II trial of IV Zybrestat given weekly for 3 weeks of a 4-week cycle in combination with once-daily oral Votrient pazopanib for up to 6 cycles in up to 128 patients with recurrent ovarian cancer who received >=1 platinum-containing regimen. The Phase Ib dose-escalation portion will evaluate of 45-60 mg/m 2 Zybrestat plus 600 or 800 mg Votrient. The Phase II portion will compare the combination selected from the Phase Ib portion vs. 800 mg Votrient. ...